Media coverage about HTG Molecular Diagnostics (NASDAQ:HTGM) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. HTG Molecular Diagnostics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 46.5218366682406 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s analysis:
- Htg Molecular Dia Cm (NASDAQ:HTGM) Sees Price Swing – Down by 6.75% – First News 24 (firstnewspaper24.com)
- HTG Molecular Diagnostics, Inc. (HTGM) Rating Reiterated by HC Wainwright – Gears Of Biz (gearsofbiz.com)
- HTG Molecular Diagnostics, Inc. :HTGM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 (finance.yahoo.com)
- HTG Molecular Diagnostics’ (HTGM) CEO TJ Johnson on Q3 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- ETFs with exposure to HTG Molecular Diagnostics, Inc. : November 8, 2017 (finance.yahoo.com)
A number of research analysts recently weighed in on HTGM shares. ValuEngine raised shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 17th. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, HC Wainwright set a $6.00 target price on shares of HTG Molecular Diagnostics and gave the company a “buy” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $6.17.
HTG Molecular Diagnostics (NASDAQ HTGM) traded down $0.18 during trading on Tuesday, reaching $2.20. 508,200 shares of the company were exchanged, compared to its average volume of 1,367,117. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $13.25.
In related news, major shareholder Holdings A/S Novo sold 80,586 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $2.07, for a total value of $166,813.02. Following the completion of the transaction, the insider now owns 1,225,085 shares of the company’s stock, valued at $2,535,925.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 1,661,889 shares of company stock valued at $3,077,980. 7.60% of the stock is owned by insiders.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.